Cargando…

Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulation

BACKGROUND: Irradiation (IR) and immune checkpoint inhibitor (ICI) combination is a promising treatment modality. However, local and distance treatment failure and resistance can occur. To counteract this resistance, several studies propose CD73, an ectoenzyme, as a potential target to improve the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meziani, Lydia, Gerbé de Thoré, Marine, Clémenson, Céline, Liu, Winchygn, Laurent, Pierre-Antoine, Mondini, Michele, Vozenin, Marie-Catherine, Deutsch, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255154/ https://www.ncbi.nlm.nih.gov/pubmed/37270182 http://dx.doi.org/10.1136/jitc-2023-006846

Ejemplares similares

Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models
por: Tran Chau, Vanessa, et al.
Publicado: (2020)

TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy
por: Hamon, Pauline, et al.
Publicado: (2022)

Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages
por: Meziani, Lydia, et al.
Publicado: (2020)

KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner
por: Laurent, Pierre-Antoine, et al.
Publicado: (2023)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines
por: Fumagalli, Ingrid, et al.
Publicado: (2015)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
por: Tripathi, Abhishek, et al.
Publicado: (2020)

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
por: Yap, Timothy A., et al.
Publicado: (2022)

Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia
por: Meziani, Lydia, et al.
Publicado: (2021)

Macrophages in radiation injury: a new therapeutic target
por: Meziani, Lydia, et al.
Publicado: (2018)

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
por: Miller, Richard A, et al.
Publicado: (2022)

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022)

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
por: Tolcher, Anthony W, et al.
Publicado: (2023)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
por: Mangoni, M, et al.
Publicado: (2012)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
por: Sun, Fan, et al.
Publicado: (2020)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Yoshida, Takashi, et al.
Publicado: (2021)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Zhu, Shaoming, et al.
Publicado: (2021)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients
por: Bosch, Ernesto, et al.
Publicado: (2011)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
por: Schetters, Sjoerd T T, et al.
Publicado: (2020)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
por: Isoyama, Sho, et al.
Publicado: (2021)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity
por: Zheng, Ming
Publicado: (2023)

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
por: Randon, Giovanni, et al.
Publicado: (2023)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
por: Shigeta, Kohei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qpgbov87tfjvdlln5fauatakma